These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6203936)

  • 21. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans.
    Przedborski S; Levivier M; Raftopoulos C; Naini AB; Hildebrand J
    Mov Disord; 1995 Jan; 10(1):28-36. PubMed ID: 7885353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Approaches to the study of dopamine metabolism in various extrapyramidal diseases].
    Barkhatova VP; Kandel' EI; Demina EG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(7):1021-9. PubMed ID: 6457476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The enhanced neuroleptic therapy and malignant syndrome].
    Jiang ZN
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1983 Apr; 16(2):84-6. PubMed ID: 6137330
    [No Abstract]   [Full Text] [Related]  

  • 25. The effects of cyanide on the extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxyindoleacetic acid and inositol phospholipid breakdown in the brain.
    Cassel GE; Koch M; Tiger G
    Neurotoxicology; 1995; 16(1):73-82. PubMed ID: 7541518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correction of an extrapyramidal neuroleptic syndrome with tryptophan and the dynamics of its concentration in the blood of patients].
    Balakleevskiĭ AI; Mitiukova TA; Vazhenin MM; Gaĭduk FM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(2):95-7. PubMed ID: 6112836
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug side effects on the nervous system].
    Ludin HP
    Ther Umsch; 1993 Jan; 50(1):23-7. PubMed ID: 8104359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic malignant syndrome with risperidone.
    Gleason PP; Conigliaro RL
    Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Malignant neuroleptic syndrome].
    Devos P; Destee A; Warot P
    LARC Med; 1984 May; 4(5):316-9. PubMed ID: 6147732
    [No Abstract]   [Full Text] [Related]  

  • 30. Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
    Van Praag HM; Korf J
    Am J Psychiatry; 1976 Oct; 133(10):1171-7. PubMed ID: 970488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
    Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A
    Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Malignant neuroleptic syndrome].
    Courtine JC; Blot P
    Nouv Presse Med; 1981 May; 10(21):1749. PubMed ID: 6112732
    [No Abstract]   [Full Text] [Related]  

  • 34. The neuroleptic malignant syndrome.
    Kimsey LR; Gibbs JT; Glen RS; Markette JR; Kosted E
    Tex Med; 1983 Oct; 79(10):54-5. PubMed ID: 6138871
    [No Abstract]   [Full Text] [Related]  

  • 35. [Acute extrapyramidal syndrome and neuroleptical malignant syndrome. A case report].
    Cesario V
    Recenti Prog Med; 2008 Mar; 99(3):146-8. PubMed ID: 18488526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome].
    Ueda M; Hamamoto M; Otsubo K; Miyazaki T; Terashi A
    Rinsho Shinkeigaku; 1996 May; 36(5):696-8. PubMed ID: 8905993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Extrapyramidal syndrome].
    Nakagawa S; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):179-82. PubMed ID: 12876960
    [No Abstract]   [Full Text] [Related]  

  • 38. [Neurotransmitters and degenerative diseases in the central nervous system].
    Nakamura S
    Nihon Ronen Igakkai Zasshi; 1986 Jan; 23(1):11-6. PubMed ID: 2423726
    [No Abstract]   [Full Text] [Related]  

  • 39. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
    Brashear A; Butler IJ; Hyland K; Farlow MR; Dobyns WB
    Ann Neurol; 1998 Apr; 43(4):521-6. PubMed ID: 9546335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.